Compare Ginkgo Bioworks Holdings Inc (DNA) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Upstart Holdings Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Upstart Holdings Inc trades at $31.83 (market cap $3.04B). The key difference: Upstart Holdings Inc is far larger — about 5.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | UPST | |
|---|---|---|
Market Cap | $590.53M | $3.04B |
Sector | Health | Financials |
52-Week High | $16.14 | $84.13 |
52-Week Low | $5.48 | $24.22 |
Enterprise Value | $627.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
UPST trades at $31.46, down 3.91% on the day, reflecting recent volatility amid mixed earnings. The stock shows a bearish technical trend with support near $29, while fundamentals highlight a return to profitability in 2025 with $1.02B revenue and $53.60M net income. Recent news emphasizes AI lending growth and a key $600M funding deal with Neuberger Berman, though margin pressures persist.
The outlook hinges on execution of AI-driven lending expansion and funding stability, with a consensus price target of $42.00 suggesting 33% upside. Risks include earnings volatility, high debt levels, and competitive fintech pressures. Analyst sentiment is balanced with 45% buy ratings, but investors await Q2 2026 results on August 4 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
